Figure 2

Induction therapy with Erlotinib (E) and Gemcitabine/Platinum (GP) in stage III NSCLC

Tobias R Overbeck*, Stefan HP Wenleder*, Bernhard C Danner, Wolfgang Körber, Karin Toepelt, Bernhard Hemmerlein, Christina Perske, Markus Falk, Markus Tiemann, Claudia Tomala, Elke Stitz and Frank Griesinger

Published: 28 January, 2021 | Volume 5 - Issue 1 | Pages: 001-018

jprr-aid1018-g002

Figure 2:

Overall survival analysis. Comparing patients with respect to pathological response after induction of E and GP + / - E, Junker regression grade RG IIb / III (major pathologic response) was associated with longer overall survival (A) and event free survival (B), n = 12 patients (4/16 patients without surgery). Comparison of response at CT / PET after Induction of E and GP + / - E showed longer overall survival (C) and event free survival (D) in patients with non-progressive disease, n = 15 patients (one patient with death before 2nd restaging). CT and PET were concordant in the matter of discrimination of progressive disease vs. non-progressive disease. These results only are descriptive.

Read Full Article HTML DOI: 10.29328/journal.jprr.1001018 Cite this Article Read Full Article PDF

More Images

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More

Help ?